中国医院用药评价与分析2024，Vol.24Issue(11)：1360-1366,7.DOI:10.14009/j.issn.1672-2124.2024.11.016
基于循证药学的环磷腺苷类药物临床现状研究
Clinical Status of Cyclic Adenosine Monophosphate Related Drugs Based on Evidence-Based Pharmacy
摘要
Abstract
OBJECTIVE:To systematically evaluate the efficacy and safety of cyclic adenosine monophosphate related drugs.METHODS:PubMed,Embase,the Cochrane Library,CNKI,Wanfang Data and CBM were retrieved to collect the systematic reviews(SR)/Meta-analyses and randomized controlled trials(RCT)of cyclic adenosine monophosphate related drugs published in the core journals of Chinese scientific and technical papers from the establishment of the database to Jan.2024,and the English database was not restricted by journals.The included literature was summarized and concluded using descriptive analysis.RESULTS:A total of 42 studies were enrolled,including 3 SR/Meta-analyses and 39 RCT.Totally 8 275 patients were involved in three kinds of cyclic adenosine monophosphate related drugs,including cyclic adenosine monophospholide,meglumine adenosine cyclophosphate and dibutyrylcalcium adenosine cyclophosphate,with 5 types of diseases,including heart failure,myocardial infarction,myocarditis,angina pectoris and psoriasis.Results showed that three kinds of cyclic adenosine monophosphate related drugs had significant therapeutic effects on myocardial infarction,myocarditis and angina pectoris,among which calcium dibutyryl cyclic adenosine phosphate had certain advantages in the treatment of psoriasis due to its special chemical structure.In terms of safety,the overall safety of cyclic adenosine monophosphate related drugs was favorable,which were within the controllable range.CONCLUSIONS:Cyclic adenosine monophosphate related drugs are effective in the treatment of myocardial infarction,myocarditis,and angina pectoris with higher safety,and calcium dibutyryl cyclic adenosine phosphate has certain advantages in the treatment of psoriasis.关键词
环磷腺苷/心肌炎/心肌梗死/心绞痛/银屑病/系统评价Key words
Cyclic adenosine monophosphate related drugs/Myocarditis/Myocardial infarction/Angina pectoris/Psoriasis/Systematic review分类
医药卫生引用本文复制引用
郑子恢,高峰,李文英,潘慧杰,原涵,胡欣,金鹏飞..基于循证药学的环磷腺苷类药物临床现状研究[J].中国医院用药评价与分析,2024,24(11):1360-1366,7.基金项目
国家卫生健康委创新药物上市后临床研究科研专项(No.WKZX2023CX210007) （No.WKZX2023CX210007）
